Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.
暂无分享,去创建一个
[1] R. McLendon,et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma , 2012, Journal of Neuro-Oncology.
[2] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[3] T. Mikkelsen,et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. , 2015, Neuro-oncology.
[4] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[5] Susan M. Chang,et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[7] W. Cavenee,et al. Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.
[8] R. McLendon,et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. , 2010, Neuro-oncology.
[9] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[10] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[11] W. Mason,et al. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Benedick A Fraass,et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Toms,et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.
[14] J. Bruna,et al. Bevacizumab for the Treatment of Glioblastoma , 2013, Clinical Medicine Insights. Oncology.
[15] P. Thall,et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. , 1995, International journal of radiation oncology, biology, physics.
[16] Fred H. Hochberg,et al. Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.
[17] D F Nelson,et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. , 1988, NCI monographs : a publication of the National Cancer Institute.
[18] S. Hansen,et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. , 2010, Neuro-oncology.
[19] T. Cloughesy,et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. , 2010 .
[20] S B Green,et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.
[21] R. McLendon,et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study , 2009, British Journal of Cancer.
[22] R. Bourgon,et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Piérart,et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] C. James,et al. Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma , 2008, Clinical Cancer Research.
[25] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Carlo Sala,et al. Antiangiogenic Therapy for Glioma , 2012, Journal of signal transduction.
[27] W. Mason,et al. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era , 2014, Journal of Neuro-Oncology.
[28] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[29] K. Camphausen,et al. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. , 2015, International journal of radiation oncology, biology, physics.
[30] B. Fisher,et al. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. , 2002, International journal of radiation oncology, biology, physics.
[31] T. Mikkelsen,et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. , 2010, The oncologist.
[32] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] W. Curran,et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. , 2013, International journal of radiation oncology, biology, physics.
[35] Katrina H. Smith,et al. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients , 2015, Clinical Cancer Research.
[36] N. Willich,et al. Combined Radiochemotherapy with Paclitaxel in the Treatment of Malignant Glioma , 2002, Strahlentherapie und Onkologie.
[37] M. Sautter‐Bihl,et al. Radiotherapy of glioblastoma multiforme , 1998, Strahlentherapie und Onkologie.
[38] K. Aldape,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[39] L. Morgan,et al. The epidemiology of glioma in adults: a "state of the science" review. , 2015, Neuro-oncology.
[40] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[41] S. Piantadosi,et al. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. , 1999, International journal of radiation oncology, biology, physics.
[42] M. Ahluwalia,et al. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges , 2013, OncoTargets and therapy.
[43] P. Graham. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[44] H. Urbach,et al. O10.04THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE , 2014 .
[45] J. Reijneveld,et al. UvA-DARE ( Digital Academic Repository ) Angiogenesis inhibition in high grade glioma Verhoeff , 2009 .
[46] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[47] J. Buckner,et al. Conditional probability of long‐term survival in glioblastoma , 2012, Cancer.
[48] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[49] M. Boniol,et al. Response to a Phase II Study of Concomitant-to-Sequential Use of Etoposide and Radiation Therapy in Newly Diagnosed Malignant Gliomas , 2003, American journal of clinical oncology.
[50] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[51] D. Brachman,et al. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. , 2015, International journal of radiation oncology, biology, physics.
[52] A. Gregory Sorensen,et al. Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.
[53] M. Guiou,et al. Novel Therapies in Glioblastoma , 2012, Neurology research international.
[54] J. Barnholtz-Sloan,et al. The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.